AM-Pharma

Executive Summary

AM-Pharma is a Netherlands-based biotechnology company focused on developing ilofotase alfa, a recombinant human alkaline phosphatase, for the treatment of adult hypophosphatasia (HPP), a rare genetic disorder. The company is currently advancing ilofotase alfa through Phase 3 clinical trials, building on earlier positive Phase 1/2 data. HPP is characterized by deficient alkaline phosphatase activity leading to skeletal and dental abnormalities, muscle weakness, and respiratory complications. Ilofotase alfa aims to restore enzyme activity and improve patient outcomes. Beyond HPP, AM-Pharma has explored ilofotase alfa in other indications such as acute kidney injury, sepsis, and open heart surgery, though those programs are less advanced. The company’s pipeline also includes HM201 for inflammatory bowel disease and earlier-stage assets, but the primary value driver is ilofotase alfa for HPP. As a private company, AM-Pharma may seek partnerships or financing to support its late-stage development and potential regulatory submission. With a clear focus on an unmet medical need and a plausible mechanism, the company represents a notable opportunity in rare disease therapeutics.

Upcoming Catalysts (preview)

• TBDPhase 3 HPP Trial Topline Data60% success
• TBDRegulatory Submission for Ilofotase Alfa in Adult HPP50% success
• H1 2026Phase 2 Open Heart Surgery Data Readout40% success